The United Kingdom (UK) is set to begin a “match-making” service called the cancer vaccine launch pad (CVLP), which can match patients with suitable trials.
In the project, which will be run by the Southampton
Clinical Trials Unit (SCTU), based at the University of Southampton, thousands
of patients will be able to access “ground-breaking” cancer vaccines as part of
an NHS trial.
The programme aims to improve patient access to clinical
trials to test new investigational immunotherapies by speeding up the
development of personalised cancer vaccines.
The vaccines are created by analysing a patient’s tumour and using that information to create a vaccine tailored to that individual.
The vaccines aim to create an immune “memory” that can
prevent cancer from returning after surgery or chemotherapy.
The first trial will be testing a vaccine under development
by the biotech company BioNTech SE.
Simon Crabb, SCTU clinical director, said the new scheme
would “bring together different academic and industry partners who are
developing cancer vaccines and allow patients across England to access trials
of treatments that may not have previously been an option for them”.
“Cancer vaccines have
the potential to improve the way we treat the disease, particularly for those
cancers where treatment options are currently limited or very demanding on
patients’ bodies,” Gareth Griffiths, director of the Cancer Research UK SCTU,
said.
Advertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com